Investigation on the current status of pharmaceutical care in medical institutions in China

ZHENG Tingting; ZHANG Yuqing; LIU Sitong; ZHANG Wei; LU Jin; SHEN Qunhong; ZHEN Jiancun

doi:10.6039/j.issn.1001-0408.2025.09.17

您当前的位置：

首页 >

文章列表页 >

Investigation on the current status of pharmaceutical care in medical institutions in China

更新时间：2025-09-23

- Investigation on the current status of pharmaceutical care in medical institutions in China
- ZHONGGUO YAOFANG Vol. 36, Issue 9, Pages: 1117-1122(2025)
- 作者机构：
  
  1.首都医科大学附属北京积水潭医院药学部，北京　100035
  2.北京大学药学院，北京　100191
  3.中国医院协会药事专业委员会，北京　100035
  4.清华大学公共管理学院卫生与发展研究中心，北京　100084
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.09.17
  CLC： R95
- Received：13 December 2024，
  
  Revised：2025-03-18，
  
  Accepted：19 March 2025，
  
  Published：15 May 2025
- 稿件说明：
移动端阅览
郑婷婷,张宇晴,刘思彤,等.我国医疗机构药学监护开展现状调查 [J].中国药房,2025,36(09):1117-1122.

ZHENG Tingting,ZHANG Yuqing,LIU Sitong,et al.Investigation on the current status of pharmaceutical care in medical institutions in China[J].ZHONGGUO YAOFANG,2025,36(09):1117-1122.
郑婷婷,张宇晴,刘思彤,等.我国医疗机构药学监护开展现状调查 [J].中国药房,2025,36(09):1117-1122. DOI： 10.6039/j.issn.1001-0408.2025.09.17.

ZHENG Tingting,ZHANG Yuqing,LIU Sitong,et al.Investigation on the current status of pharmaceutical care in medical institutions in China[J].ZHONGGUO YAOFANG,2025,36(09):1117-1122. DOI： 10.6039/j.issn.1001-0408.2025.09.17.

摘要

目的

调查我国医疗机构药学监护开展现状，为药学监护持续发展提供经验和建议。

方法

采用问卷调查法，于2023年3月调研31个省（自治区、直辖市）医疗机构药学监护的开展情况，对结果进行描述性分析，并对药学监护开展的影响因素进行二元Logistic回归分析。

结果

共发放问卷1 368份，收回有效问卷1 304份，问卷有效回收率为95.32%。有671家（51.46%）医疗机构开展了药学监护，其中三级、二级、一级及其他医疗机构药学监护开展率分别为74.79%、27.97%、7.35%。平均年药学监护服务患者量为2 638.96人次，平均每家医疗机构有8.33名药师开展药学监护，开展药学监护药师中有93.68%是临床药师。药学监护服务覆盖的主要科室包括呼吸与危重症医学科、心内科、重症医学科、内分泌科、肿瘤科、消化内科、妇产科等。对药学监护服务有额外补偿的医疗机构为48家（7.15%）。开展药学监护的主要经验是重视人才培养和重视学科建设，面临的主要困难是人员短缺、符合要求的人才严重不足和补偿水平低、开展的积极性不高。医疗机构等级、医疗机构从事临床药学工作的药师数量、医疗机构有临床药师资质的药师数量以及医疗机构药学部信息化程度是开展药学监护的主要影响因素（

＜0.05）。

结论

近年来我国医疗机构药学监护取得了一定进展，但一、二级及其他医疗机构药学监护开展率仍有较大的提升空间。后续仍需进一步推进药学监护开展、加强人才培养、重视药学监护价值体现，进而促进药学监护可持续、高质量发展。

Abstract

OBJECTIVE

To investigate the current status of pharmaceutical care in medical institutions in China， and provide experience and suggestions for better development of pharmaceutical care.

METHODS

Questionnaire survey was used to investigate the development of pharmaceutical care in medical institutions in 31 provinces （autonomous regions and municipalities directly） in March 2023， and descriptive analysis and binary logistic regression analysis on the influencing factors of pharmaceutical care were conducted.

RESULTS

A total of 1 368 questionnaires were sent out， and 1 304 valid questionnaires were collected with the effective recovery rate of 95.32%. Pharmaceutical care was carried out in 671 medical institutions （51.46%）， and the rates of pharmaceutical care in tertiary， secondary， primary and other medical institutions were 74.79%， 27.97% and 7.35%， respectively. The average number of patients receiving pharmaceutical care was 2 638.96 per year， and there were 8.33 pharmacists in each medical institution to carry out pharmaceutical care， among which 93.68% were clinical pharmacists. The main departments covered by pharmaceutical care services included respiratory and critical care medicine， cardiology， intensive care unit， endocrinology， oncology， gastroenterology， obstetrics and gynecology and other departments. There were only 48 medical institutions （7.15%） with additional compensation for pharmaceutical care services. The main experiences of developing pharmaceutical care were to pay attention to talent cultivation and discipline construction， but the main difficulties were serious shortage of staff and qualified talents， low compensation level and low enthusiasm. Grade of medical institutions， the number of pharmacists engaged in clinical pharmacy， the number of qualified clinical pharmacists and the degree of information in the pharmacy department were the main influencing factors for carrying out pharmaceutical care （

＜0.05）.

CONCLUSIONS

In recent years， pharmaceutical care in Chinese medical institutions has made certain progress， while that of primary medical institutions， secondary medical institutions and other medical institutions should be improved. In the future， it is still necessary to further enhance the implementation of pharmaceutical care， promote personnel training， and attach importance to demonstrating the value of pharmaceutical care， thereby promoting the sustainable and high-quality development of pharmaceutical care.

关键词

Keywords

references

中国医院协会药事专业委员会《医疗机构药学服务规范》编写组 . 医疗机构药学服务规范：二：用药咨询、用药教育、药学查房、用药监护、居家药学服务 [J ] . 中国药房， 2019 ， 30 （ 24 ）： 3313 - 3324 .

国家卫生健康委办公厅 . 国家卫生健康委办公厅关于印发医疗机构药学门诊服务规范等5项规范的通知 [EB/OL ] .（ 2021-10-13 ）[ 2024-11-20 ] . http：//www.nhc.gov.cn/yzygj/s7659/202110/f76fc77acd87458f950c86d7bc468f22. shtml http://www.nhc.gov.cn/yzygj/s7659/202110/f76fc77acd87458f950c86d7bc468f22.shtml .

侯文婧，沈素，温爱萍，等 . 药学监护标准制订与解析 [J ] . 医药导报， 2022 ， 41 （ 10 ）： 1445 - 1448 .

王智超，武丹威，邵晓楠，等 . 我国药学监护现状调查与补偿机制探讨 [J ] . 中国医院， 2020 ， 24 （ 2 ）： 16 - 19 .

国家卫生健康委员会 . 中国卫生健康统计年鉴：2023 [M ] . 北京：中国协和医科大学出版社， 2024 ： 1 - 23 .

HEPLER C D ， STRAND L M . Opportunities and responsibilities in pharmaceutical care [J ] . Am J Hosp Pharm ， 1990 ， 47 （ 3 ）： 533 - 543 .

American Society of Hospital Pharmacists . ASHP statement on pharmaceutical care [J ] . Am J Hosp Pharm ， 1993 ， 50 ： 1720 - 1723 .

HENMAN M C ， RAVERA S ， LERY F X . Council of Europe resolution on the implementation of pharmaceutical care：a step forward in enhancing the appropriate use of medicines and patient-centred care [J ] . Healthcare （Basel）， 2024 ， 12 （ 2 ）： 232 .

ELDOOMA I ， MAATOUG M ， YOUSIF M . Outcomes of pharmacist-led pharmaceutical care interventions within community pharmacies：narrative review [J ] . Integr Pharm Res Pract ， 2023 ， 12 ： 113 - 126 .

SCHNEIDER P J ， PEDERSEN C A ， GANIO M C ， et al . ASHP national survey of pharmacy practice in hospital settings：clinical services and workforce：2021 [J ] . Am J Health Syst Pharm ， 2022 ， 79 （ 18 ）： 1531 - 1550 .

SCHNEIDER P J ， PEDERSEN C A ， GANIO M C ， et al . ASHP national survey of pharmacy practice in hospital settings：operations and technology：2023 [J ] . Am J Health Syst Pharm ， 2024 ， 81 （ 16 ）： 684 - 705 .

中共中央，国务院 . 关于深化医药卫生体制改革的意见 [EB/OL ] .（ 2009-03-17 ）[ 2024-11-20 ] . https：//www.gov.cn/gongbao/content/2009/content_1284372.htm https://www.gov.cn/gongbao/content/2009/content_1284372.htm .

国家卫生健康委，教育部，财政部，等 . 关于印发加强医疗机构药事管理促进合理用药的意见的通知 [EB/OL ] . （ 2020-02-21 ）[ 2024-11-20 ] . https：//www.gov.cn/gongbao/content/2020/content_5522549.htm https://www.gov.cn/gongbao/content/2020/content_5522549.htm .

国家卫生健康委，国家中医药管理局，国家疾控局 . 关于印发全国医疗服务项目技术规范（2023年版）的通知 [EB/OL ] . （ 2023-09-20 ）[ 2024-11-20 ] . http：//www.nhc.gov.cn/caiwusi/s7785t/202309/914aec9618944ee2b36621-d33517e576.shtml http://www.nhc.gov.cn/caiwusi/s7785t/202309/914aec9618944ee2b36621-d33517e576.shtml .

北京市医疗保障局，北京市人力资源和社会保障局 . 关于新增及动态调整抗水通道蛋白抗体测定等医疗服务价格项目和相关政策的通知 [EB/OL ] .（ 2024-08-16 ）[ 2024-11-20 ] . https：//www.beijing.gov.cn/zhengce/zhengcefagui/202410/t20241014_3918633.html https://www.beijing.gov.cn/zhengce/zhengcefagui/202410/t20241014_3918633.html .

郑婷婷，邵晓楠，吴岢非，等 . 我国医院药学门诊现状调查及对策研究 [J ] . 中国医院， 2020 ， 24 （ 2 ）： 5 - 7 .

杨烁，邵晓楠，吴岢非，等 . 国内外药物重整服务现状及补偿机制探讨 [J ] . 中国医院， 2020 ， 24 （ 5 ）： 60 - 62 .

杨雅麟，杨丽娟，刘思彤，等 . 国内外药学查房现状及补偿机制探讨 [J ] . 中国医院， 2020 ， 24 （ 2 ）： 20 - 23 .

卫生部，国家中医药管理局，总后勤部卫生部 . 关于印发《医疗机构药事管理规定》的通知 [EB/OL ] .（ 2011-03-30 ）[ 2024-11-20 ] . http：//www.nhc.gov.cn/yzygj/s3593/201103/4119b5de252d45ac916d420e0d30fda7.shtml http://www.nhc.gov.cn/yzygj/s3593/201103/4119b5de252d45ac916d420e0d30fda7.shtml .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical efficacy and influencing factors of ceftazidime and avibactam monotherapy versus combination therapy in the treatment of CRGNB infection

Study on the influential factors for clinical efficacy of polymyxin B combined with other antibiotics in the treatment of carbapenem-resistant Acinetobacter baumannii pulmonary infection

药物防治糖皮质激素性骨质疏松的规范性及影响因素分析

Characteristics and influencing factors of immune-related adverse events in patients with extensive-stage small cell lung cancer treated with immune checkpoint inhibitors

Analysis of influencing factors on the inclusion of Chinese patent medicines in the national reimbursement drug list

Related Author

LIU Changwei

WANG Xiaohua

ZHANG Hui

WANG Ranran

XIAO Rongcheng

FANG Ling

DU Mei

TAN Ruijuan

Related Institution

Dept. of Infectious Diseases， the First Affiliated Hospital of Anhui Medical University

Grade Ⅲ Pharmaceutical Chemistry Laboratory of TCM， National Administration of Traditional Chinese Medicine

Dept. of Pharmacy， the First Affiliated Hospital of Anhui Medical University

Dept. of Rehabilitation Medicine， Hengshui Municipal People’s Hospital

Dept. of Pharmacy， Hengshui Municipal People’s Hospital

⁰